Skip to main content
Caplight Logo









Caris Life Sciences

Caris Life Sciences

Public

Caris Life Sciences is now publicly traded

The data on this page reflects Caris Life Sciences's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

Jun 17, 2025

Last Round

Growth Equity

Apr 7, 2025

Total Funding Raised

$2.12B

Company Overview

Caris Life Sciences is a biotechnology company that provides precision medicine solutions through molecular profiling and artificial intelligence to support cancer treatment decisions.

Sector

Biotech

AI Layer

Application

Keywords

precision medicinemolecular profilingtumor profilingliquid biopsywhole exome sequencingWESwhole transcriptome sequencingWTScancer biomarkersclinical decision supportoncology diagnosticsbiotechclinico-genomic databasebiomarker discoveryAI diagnosticsmedtech

Caris Life Sciences Comparables

Compare Caris Life Sciences with similar companies based on industry and business-model similarity.

Caris Life Sciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tempus
90%
Guardant Health
87%
Personalis Inc
79%

Caris Life Sciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
IPOJun 17, 2025
Growth EquityApr 7, 2025
DebtJan 19, 2023
Growth EquityMay 11, 2021
DebtOct 27, 2020
Debt
Oct 1, 2018

Key People

Founding team and executive leadership

Luke Power

Chief Financial Officer

Executive Team

Caris Life Sciences Investors

Notable investors and investment history

Caris Life Sciences investors
InvestorRounds
CPP InvestmentsGrowth Equity
Evercore ISIipo
Perceptive AdvisorsGrowth Equity
Guggenheim Securitiesipo
Millennium ManagementGrowth Equity, Debt
BraidwellDebt, Growth Equity
Columbia Threadneedle InvestmentsGrowth Equity

Recent news

Latest coverage and updates

  • has_earningsAug 24, 2026

    Caris Life Sciences had earnings of $55.7M on Aug 5th '26.

  • launchesJul 14, 2026

    Caris Life Sciences launched in-house PTEN immunohistochemistry on Jul 14th '26.

  • launchesJul 6, 2026

    Caris Life Sciences, Ltd. launches blood test designed to detect early signals for multiple types of cancer.

Caris Life Sciences Filings

Explore SEC and related filing metadata, where available.

Caris Life Sciences filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersIrving, Texas
Employee Range1,632
Year Founded2008
Last FundingApr 7, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?